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S U M M A R Y
Background: Enterovirus 71 (EV71), amember of the Enterovirus genus of the Picornaviridae family, is one
of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological
agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an
increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective
antiviral agents and vaccines against this virus are currently still under development. We reviewed
publications on the development of EV71 vaccines in order to provide an overview of the ﬁeld.
Methods: Fifty-ﬁve articles on EV71 vaccine development, published from 1974 to 2009, were collected
from Sun Yat-sen University library and reviewed.
Results: Various types of vaccine have been developed for EV71. In results published to date, all vaccines
for EV71 under development appear to elicit an immune response in rodents or inmonkeys. According to
the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated
virus in order tomeet the immediate demands for EV71 control .With regard to the attenuated vaccine, it
is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The
virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk
of virulent revertants, is another promising vaccine candidate for EV71, but needs further development.
The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope
vaccine; these remain viable potential vaccine strategies worthy of further study and development.
Conclusions: The conservation of the three-dimensional structure is important for the EV71 inactivated
vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high
protection efﬁcacy, strategies such as the use of adjuvant, strong promoters, tissue-speciﬁc promoters,
and addition of mucosal immune adjuvant should be considered.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Enterovirus 71 (EV71), a member of the Enterovirus genus of the
Picornaviridae family, is the most frequently detected pathogen in
hand-foot-and-mouth disease (HFMD) patients complicated with
neurological dysfunction.1 EV71 was ﬁrst isolated in California in
1969,2 and its association with HFMD was veriﬁed in 1974.3,4 It
was later conﬁrmed as the causative agent responsible for HFMD
outbreaks in Hungary,5 Australia,6 Hong Kong,7 Taiwan,8 Japan,9
and Singapore.10 Moreover, in 2008 and 2009, a large outbreak
occurred in Mainland China.11–13 Children under 5 years of age
have been found to be particularly susceptible to the severest form
of EV71-associated neurological disease.14 This is an important
public health problem causing serious clinical illness and,
potentially, death in young children.* Corresponding author. Tel.: +86 20 87330605; fax: +86 20 87332438.
E-mail address: jiahailu@yahoo.com.cn (J. Lu).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.12.002EV71 possesses a single-stranded RNA genome of approxi-
mately 7500 nucleotides, consisting of a single open reading frame
(ORF) ﬂanked by 50-untranslated regions (50UTR) and 30-untrans-
lated regions (30UTR). The ORF is expressed as a large polyprotein
that can be cleaved into P1, P2, and P3 regions. The P1 region
encodes four structural proteins VP1, VP2, VP3, and VP4. The P2
and P3 regions encode nonstructural proteins, such as proteases
2A, 2B, and 3CD, responsible for virus replication and virulence.
Protease 2A autocatalytically cleaves P1 at its N-terminus and
liberates P1 from the nascent polyprotein,15 while protease 3CD
cleaves the P1 precursor into VP1, VP3 and VP0 (VP2 and VP4).
These three structural proteins spontaneously assemble and form
the crystalline virus-like particles.16
Though there has been a signiﬁcant increase in EV71 epidemic
activity throughout the Asia-Paciﬁc region, effective antiviral
therapies and vaccines have, to-date, not been available. The
development of effective vaccines is a top priority in terms of
control strategies. Below is an overview of the ﬁeld of EV71 vaccine
preparation to date.ses. Published by Elsevier Ltd. All rights reserved.
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As conventional vaccines, inactivated virus vaccines, such as
inactivated inﬂuenza vaccine17 and inactivated hepatitis A
vaccine,18 have been successfully used in the human. Sero-
epidemiologic studies have indicated that the preexisting neu-
tralizing antibody to EV71 is protective against the severe
outcomes of infection.8,19 Yu et al.20 and Wu et al.21 showed that
passive transfer of serum from formalin-inactivated and heat-
inactivated virus vaccine immunized adult mice, could provide
protection against EV71 challenge in neonatal mice; meanwhile,
maternal immunization with inactivated EV71 vaccine was able to
prolong the survival of suckling mice after EV71 lethal challenge.
These results show the value of the inactivated virus vaccine for the
effective control of EV71. However, the conservation of the three-
dimensional structure is important in order to induce a strong
immune response. Therefore, for the heat-inactivated virus, a
much higher dose of viral antigen and adjuvant are required to
achieve an acceptable level of immunogenicity and protection.
Obviously, an ideal vaccine strain is required for the large-scale
preparation of the inactivated EV71 vaccine, as has been the case
for the Sabin oral polio vaccine (OPV) strain. Lin et al.22 developed
an EV71 strain, YN3-4a, exhibiting a rapid growth rate in Vero cells
with a larger plaque size and a lower lethal dose (LD)50 in newborn
mice. Lin and coworkers showed that mouse antiserum raised
against YN3-4awas able to neutralize a broad range of EV71 strains
isolated from patients of a variety of geographic origins at different
points in time. YN3-4a possesses desirable features, such as a high
viral yield, the ability to propagate in serum-free medium, and
strong immunogenicity, as well as broad-based antigenic coverage
and passage stability, indicating its potential for development as an
inactivated vaccine strain.
A powerful cell system is also important in the development of
an inactivated vaccine. As shown byWu and coworkers,23 a serum-
free Vero cell culture with a 5 g/l Cytodex 1 microcarrier
concentration in a 2-l bioreactor has also been established,
yielding a high titer of 5.8  107 TCID50/ml EV71 production. On
the basis of the study of Wu et al.,23 Liu et al.24 showed that the
serum-free culture increased post-infection cell death and reduced
the virus productivity, but elicited a higher neutralizing antibody
titer in immunized mice as compared to the serum-containing
cultures. Therefore, the serum-free microcarrier culture is a
valuable technique for developing inactivated EV71 vaccines on
a large scale.
3. Attenuated strain vaccine
An example of a successful attenuated strain vaccine is Sabin
OPV. This was introduced in the early 1960 s due to its easier
administration, lower cost, and higher intestinal muscosal
immunity than the inactivated polio vaccine (IPV), and has since
been approved for worldwide application for poliovirus eradica-
tion.25,26 Because of the similarities between poliovirus and EV71,
Arita et al.27,28 have developed an EV71 attenuated strain, EV71
(S1-30), carrying mutations in the 50UTR, 3D polymerase (3Dpol)
and 30UTR 50 non-translated based on the attenuation determi-
nants of poliovirus. This EV71 (S1-30) strain is characterized by
attenuated neurovirulence and limited spread of virus. In a
subsequent study by Arita et al.,29 three cynomolgus monkeys
were inoculated with EV71 (S1-30), followed by a lethal challenge
with the parental virulent strain EV71 (BrCr-TR); they suffered
mild neurological symptoms (tremor), but survived the lethal
challenge without exacerbation of the symptoms. Moreover, the
sera from the immunized monkeys showed a broad spectrum of
neutralizing activities against different genotypes of EV71. These
ﬁndings indicate that EV71 (S1-30) acts as an effective antigen.However, it does cause mild neurological symptoms when
inoculated via the intravenous route. Additional studies are
required to ensure that further attenuation produces effective
attenuated vaccine strains. EV71 infection via the oral route did not
efﬁciently cause neurological disorders in the inoculatedmonkeys.
Therefore the cynomolgus monkeys were inoculated by intrave-
nous route instead of the oral route to evaluate the antigenicity of
the attenuated EV71 vaccine. Thus, to develop an oral EV71
attenuated vaccine, a valid animal model of EV71 infection by the
oral route is urgently needed.
Meanwhile, it is well known that in a small number of OPV
recipients and their close contacts, especially those with primary
humoral immunodeﬁciencies, the vaccine strain can mutate to a
neurovirulent strain during OPV replication and cause vaccine-
associated paralytic poliomyelitis (VAPP), which is an adverse side
effect of OPV.30–32 A 1969WorldHealth Organization Collaborative
study found that the VAPP rate was one in every 5.9 million doses
administered for vaccine recipients and one in every 6.7 million
doses administered for contacts.33 Therefore, the genetic stability
of the attenuated OPV is a major concern, and efforts should be
made to further attenuate the neurotoxic effects and increase the
genetic stability of the attenuated EV71 vaccine before clinical use.
4. Subunit vaccine
To overcome the potential problem of reversion to virulence of
attenuated strain vaccine, subunit vaccines consisting of only one
or a few ‘subunit’ proteins of the pathogen that can stimulate
immune responses directed at the intact virus have been
developed using recombinant DNA technology. In common with
other enteroviruses, the VP1, VP2, and VP3 of EV71 are responsible
for the antigenic diversity of enteroviruses, but the VP1, the major
capsid protein of EV71, is clustered with neutralization epitopes
and has the potential to act as an antiviral subunit vaccine.34
Wu et al. 21 have described a recombinant VP1 protein
expressed in Escherichia coli BL21, showing that the VP1 protein
with a complete adjuvant is able to elicit a neutralizing antibody
response, enhance T helper cell proliferation, and induce high
levels of interleukin (IL)-10 and interferon (IFN)-g in mice,
providing direct evidence that the VP1 protein contains neutraliz-
ing epitopes independent of other viral capsid proteins; this paves
the way for the use of VP1 as a backbone antigen for developing
subunit vaccines against EV71.
Transgenic edible plants and mammalian glands are possible
alternatives to prokaryotic and eukaryotic cell culture systems,
offering a palatable oral delivery system, which can elicit a good
mucosal immune response as well as systemic humoral and
cellular immune responses, making it particularly suitable for
protecting against infectious agents intruding via the mucosal
surface.35,36 EV71 initiates disease following implantation in the
gut mucosa, showing the potential of an oral vaccine for
immunization against EV71 infection. Chen and colleagues37 have
developed VP1-expressing transgenic tomato fruits. These were
used as a mouse free-feeding oral vaccine. The VP1-speciﬁc fecal
IgA and serum IgG were then observed in mice, and both humoral
and cellular immunity against EV71were established, showing the
potential use of the transgenic tomato as an oral vaccine.
Meanwhile, other EV71 oral VP1 vaccine delivery systems, such
as milk of transgenic mice described by Chen et al.38 and the
Salmonella-based method by Chiu et al.39 have been extensively
explored.
For oral vaccines, gastric acid and enzymatic digestion are
major concerns, since they may interfere with vaccine absorption.
The Enterovirus genus can withstand human gastric acid and
remain infectious below pH 3.0. However, VP1 is a capsid protein
on the surface of the EV71 particle, and whether it can resist
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digestive enzymes may also degrade the antigens. In the
experiment of Chen et al., mice gavaged with VP1 protein
produced more VP1-speciﬁc antibodies than mice fed transgenic
tomato containing more VP1 protein, in both sera and feces,
indicating that chewing and digestion cause degradation of VP1
antigen.37 Also, the oral rotavirus VP4 protein vaccine has been
shown to provide lower levels of antibodies and less protection
than immunization by injection of the rotavirus VP4 protein,40
indicating the possible interference of digestive enzymes. More-
over, it has been difﬁcult to determine the precise dose of antigens
for immunization, since competition with food and microbial
antigens interferes with the absorption rate of vaccine compo-
nents. Therefore, to improve oral vaccine delivery, many strategies
have been developed, such as using tissue-speciﬁc promoters, the
addition of mucosal immune adjuvant, using liposomes to protect
the fusion peptides in the phospholipid bilayer vesicles from the
gastric enzymes, and N-trimethyl chitosan nanoparticles.41,42 For
the oral EV71 VP1 subunit vaccine, exploring strategies to protect
antigens from enzyme degradation in the gut is necessary.
5. DNA vaccine
DNA vaccines are expressed intracellularly in the same manner
as during natural viral infection and can stimulate either humoral
immunity, cellular immunity, or both.43 Also, DNA vaccines only
deliver the target subunit antigen and thus cause fewer adverse
effects, making them another valuable vaccine choice for most
viral infections.
Tung and co-workers44 developed an EV71 DNA vaccine by
inserting the VP1 gene into a eukaryotic expression vector and
evaluated the immune response in mice. Their study results
showed that the anti-VP1 IgG level increased in mice immunized
with DNA vaccine; in contrast, this level declined after boosting
immunization. Furthermore, although the anti-VP1 IgG exhibited
neutralizing activity against EV71, the neutralizing effect of the
sera of mice immunized with the VP1 DNA vaccine was much
lower than that of EV71-infected human serum. Another DNA
vaccine developed byWuet al.,21 elicited a high neutralization titer
and stable titer level, which could be detected even at a late post-
immunization time. However, because the DNA vaccine contains
fewer antigenic epitopes, it induces a weaker immune stimulation
than the whole virus particles. Therefore, strategies to increase the
immune stimulation ability of DNA vaccines have been developed
including: incorporation of immunostimulatory sequences in the
backbone of the plasmid, co-expression of stimulatory molecules,
use of localization/secretory signals, and an appropriate delivery
system, as well as adjuvants and optimization of transgene
expression.43,45–47 All these techniques can help to prepare a better
EV71 DNA vaccine.
6. Epitope peptide vaccine
An epitope peptide vaccine consisting of a well-deﬁned
immunogenic epitope stimulates an effective and speciﬁc protec-
tive immune response while avoiding potential undesirable
effects.
The host immune response developed upon any viral infection
is primarily CD4+ T cell-dependent, including the induction of a
cytotoxic cellular response and efﬁcient antibody response. Thus,
identiﬁcation of CD4+ T cell epitopes and B cell epitopes is of great
importance in the design of effective epitope peptide vaccines. Foo
and colleagues48–50 have published several studies aimed at
identifying the T-cell and B-cell epitopes of EV71. In these studies,
they identiﬁed three regions, 66–77, 145–159, and 247–261,
spanning amino acids of the VP1 protein; they showed that thesethree regions could induce proliferation of CD4+ T cells, then
producing abundant IL-2 and IFN-g upon stimulation. Additional-
ly, among the three peptides, amino acids 145–159 induced the
strongest proliferative response and highest cytokine production.
Furthermore, in order to identify the neutralizing linear epitopes,
95 overlapping synthetic peptides spanning the VP1 capsid protein
of EV71were used to immunizemice.49 Peptides containing amino
acids 163–177 and 208–222 of VP1 protein were capable of
eliciting neutralizing antibodies against EV71, and the neutralizing
antibodies elicited by the synthetic peptide 208–222 were able to
confer good in vivo passive protection against homologous and
heterologous EV71 strains in suckling Balb/c mice.50 Moreover, the
monoclonal antibody generated by immunizing mice with amino
acids 208–222 of VP1 showed strong neutralizing activity against
EV71 in an in vitro neutralization assay.51 Therefore, the epitope
peptide vaccine represents a promising candidate for EV71. The
identiﬁcation of more T-cell and B-cell epitopes of the VP1 protein,
as well as a combination epitope peptide vaccine, should be
considered in the search for a more effective epitope peptide
vaccine.
7. Virus-like particle (VLP) vaccine
VLPs are empty particles composed of all major structural
proteins, mimicking the organizations and conformations of the
native particles. To date, it has been shown that awide range of VLPs
of clinically important viruses (e.g., HIV and severe acute respiratory
syndrome coronavirus) induce effective neutralizing antibodies and
cytotoxic T cell responses.52,53 The VLP vaccine, not only conserving
the conformational epitopes, but also having no risk of virulent
revertants, is also a promising vaccine strategy for EV71.
Hu et al.16 and Chung et al.54 used a recombinant baculovirus
expression system to express the 3CD and P1 proteins of EV71; the
3CD protein cleaves P1 precursor into VP1, VP3, and VP0, which
spontaneously assemble to form VLPs, inducing both Th1 and Th2
immune responses. More importantly, the VLP immunization of
mother mice conferred protection to neonatal mice against the
lethal viral challenge, indicating EV71 VLP to be a promising
vaccine. Chung et al.55 also found that compared with the intact
VLPs, the denatured VLPs elicited signiﬁcantly lower levels of
neutralizing antibodies and conferred lower degrees of protection
against virus challenge, which highlights the importance of
preserving the conformation-dependent epitopes in preventing
EV71 infection.
At present, the VLPs are mostly developed using insect cells and
the strict culture conditions limit the required large scale of
vaccine production. Thus, transgenic plants or yeast that can
produce VLPs to be delivered by either oral administration or
injection, might be promising expression systems.
8. Prospects
EV71 is one of the causative pathogens of HFMD, often
complicated with neurological disorders. Due to the similarities
between poliovirus and EV71 in many virological and clinical
aspects, the success of the oral polio vaccine and inactivated-virus
preparation in controlling poliomyelitis and eradicating the
poliovirus, highlight the potential for controlling EV71 by
vaccination. Poliovirus vaccine technology, both live attenuated
and inactivated virus vaccines, can be adapted to control EV71
infection.
In recent years, various types of vaccine against EV71 have been
developed, but these have as yet remained at the preclinical stage.
Outbreaks of EV71 have been reported around the world since
1969. In economically developed nations, it typically causes a mild
illness, and most patients usually recover quickly. However, since
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epidemics, and it has emerged as a serious threat to public health
throughout the Asia-Paciﬁc region. Developed countries with the
resources for vaccine research and development do not view EV71
as a priority, and the vaccine industry in developed countries has
little incentive to develop a vaccine to EV71. At present, there are
only a few vaccine industries in the Asia-Paciﬁc region undertaking
EV71 vaccine preparation. Therefore, to effectively control EV71,
more effort and cooperation worldwide is needed.
Because EV71 mainly threatens the children in developing
countries, an ideal EV71 vaccine would have to be inexpensive,
safe, convenient to administer, and acceptable to parents. For the
inactivated virus vaccine, the established regulatory standards
may allow a license to be obtained to meet the immediate
demands for EV71 control. Due to the need to conserve the three-
dimensional structure, the formalin-inactivated virus vaccine is a
potential candidate vaccine for EV71. An oral EV71 attenuated
vaccine has the potential to control EV71 in the same way as OPV
controlling poliovirus, though further attenuation procedures are
needed. At present, there are ﬁve genotypes of EV71. Cross-
protection to the different genotypes for all the EV71 vaccines
under current development is unclear. Hence, the preparation of a
vaccine strain providing wide cross-protection is another impor-
tant issue for EV71 vaccine development.
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